Project Grant R01AG084552

Award Date 8/1/24
Completion Date 4/30/29
Dollars Obligated $2.8M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98108, USA
Similar Awards
This $1,823,353 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the Seattle Institute For Biomedical And Clinical Research aims to elucidate the molecular mechanisms by which pathological tau protein causes neurodegeneration in Alzheimer's disease (AD) and related tauopathy disorders. The research project will leverage a C. elegans model of tauopathy to investigate the functional role of nuclear speckles, membraneless organelles involved in RNA...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $1,592,854 to the University of Illinois to conduct research on tau protein conformation and its role in Alzheimer's disease and related dementias. The key focus areas include: Defining the effects of tau post-translational modifications on tau function and pathology. This will evaluate how modifications like phosphorylation, acetylation, and cross-linking impact the exposure of tau's regulatory...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will be used to develop a human-mouse chimeric brain model for studying tau pathology in human neurons in vivo. The $274,750 award will enable the researchers at Purdue University to characterize the spatiotemporal patterns of tau pathology and associated cognitive dysfunction...
This Project Grant award of $320,000 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is supporting research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the impact of pathological tau protein on alternative polyadenylation (APA) regulation in Alzheimer's disease. The study aims to comprehensively profile APA transcripts and gene expression in mouse primary hippocampal neurons expressing wild-type and mutant tau proteins....
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) provides $307,312 to The University of Iowa to investigate the reversal of tau protein pathology in serotonergic neurons as a potential therapeutic intervention for early Alzheimer's disease. The research aims to determine if reversing tau hyperphosphorylation can rescue serotonergic neuron function and mitigate the propagation of tau pathology. This 1.5-year project...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...
The National Institute on Aging (NIA) awarded a $1,859,444 Project Grant (CFDA 93.866 - Aging Research) to The University of Texas Health Science Center at San Antonio to investigate the role of the lipid sulfatide in the development of tau protein pathology in the context of Alzheimer's disease and related dementias. The research aims to extensively examine whether sulfatide deficiency leads to increased tau phosphorylation, accumulation, and aggregation in oligodendrocytes, determine the...
This Project Grant award of $816,661 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support a comprehensive research project entitled "Aberrant Proteomes in Tauopathy: Revealing Functional Consequences via Multimodal Proteomics". The research, conducted by The Regents of the University of California, San Francisco, aims to systematically elucidate the molecular and cellular mechanisms by which pathological tau drives neurodegeneration in Alzheimer's disease...
This three-year, $4,349,236 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The University of South Florida will investigate the role of the BIN1 gene in modulating Alzheimer's disease tau neuropathology in vivo. Researchers will generate cell-type specific inducible BIN1 knockout mice to characterize tau pathogenesis using longitudinal MRI and neuropathology. They will test...

INVESTIGATING HOW SUT-6/NIPP1 REGULATES PATHOLOGICAL TAU - BACKGROUND: ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES WITH ACCUMULATION OF PATHOLOGICAL TAU PROTEIN, TERMED TAUOPATHIES, ARE INCREASING IN PREVALENCE AND BURDEN TO THE US POPULATION. HOWEVER, THERE ARE STILL NO THERAPIES TO CURE OR REVERSE TAUOPATHIES. DESPITE STRONG EVIDENCE THAT PATHOLOGICAL TAU CAUSES NEURODEGENERATION AND THE DEVELOPMENT OF NUMEROUS MODELS OF TAU TOXICITY, THE MOLECULAR MECHANISMS UNDERLYING THE TOXICITY INDUCED BY PATHOLOGICAL TAU ARE STILL INCOMPLETELY UNDERSTOOD. TO DISCOVER NOVEL GENETIC SUPPRESSORS OF TAU TOXICITY, FORWARD GENETIC SCREENING WAS PERFORMED IN A CAENORHABDITIS ELEGANS MODEL OF TAUOPATHY. A W292X MUTATION IN SUT-6 (NIPP1 IN MAMMALS) WAS RECENTLY IDENTIFIED AS A NOVEL MODULATOR OF TAUOPATHY. SUT-6/NIPP1 IS A MULTIFUNCTIONAL, MULTIDOMAIN PROTEIN THAT REGULATES PHOSPHATASE ACTIVITY, SPLICING OF MRNAS, AND GENE TRANSCRIPTION. THE W292X MUTANT OF SUT-6 REMOVES THE LAST 11 AMINO ACIDS OFF THE C- TERMINUS OF SUT-6 AND SHOWS STRONG, DOMINANT AND CELL-AUTONOMOUS SUPPRESSION OF TAU-INDUCED TOXICITY WHILE LOSS OF SUT-6 EXPRESSION SHOWS WEAKER SUPPRESSION OF TAU-INDUCED TOXICITY. THIS SUGGESTS THAT ALTERING SUT- 6/NIPP1 INTERACTIONS WITH PROTEIN PARTNERS THAT REGULATE PHOSPHATASE, SPLICING, OR OTHER ACTIVITIES LEADS TO SUPPRESSION OF TAU TOXICITY. HYPOTHESIS: SUT-6/NIPP1 MODULATES TAU TOXICITY BY ALTERING PROTEIN PHOSPHATASE 1 AND/OR SPLICING ACTIVITY IN TRANSLATIONALLY CONSERVED MECHANISMS OF DISEASE. PROPOSAL AIMS: THE SPECIFIC AIMS OF THIS PROJECT ARE: 1) DEFINE THE FUNCTIONS OF SUT-6/NIPP1 IMPORTANT FOR SUPPRESSING TAU TOXICITY BY INTRODUCING MUTATIONS INTO THE SUT-6 GENE AND EVALUATING THE EFFECTS IN A C. ELEGANS MODEL OF TAU PATHOLOGY. 2) DETERMINE DOWNSTREAM MEDIATORS OF SUT-6/NIPP1'S SUPPRESSION OF TAU TOXICITY BY IDENTIFYING NEURONAL INTERACTORS OF SUT-6 AND NIPP1 AND PERFORMING EPISTASIS ANALYSIS OF IDENTIFIED INTERACTORS IN A C. ELEGANS MODEL OF TAU PATHOLOGY. 3) EXAMINE THE TRANSLATIONAL IMPACT OF NIPP1 MODULATION ON TAUOPATHY USING A MOUSE MODEL OF TAU PATHOLOGY. EXPECTED OUTCOMES: THE PROPOSED STUDIES WILL DEEPEN OUR UNDERSTANDING OF A NOVEL, TRANSLATIONALLY RELEVANT MECHANISM FOR REGULATING TAUOPATHY AND OUR OVERALL KNOWLEDGE OF THE MECHANISMS OF TAU-INDUCED TOXICITY, PATHOLOGY AND DISEASE GENERALLY. THIS KNOWLEDGE WILL LEAD TO BETTER THERAPEUTIC STRATEGIES TARGETING TAU IN ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES.

Posted 7/26/24